- Home
- BRSP vs AVIR Comparison
BRSP vs AVIR Comparison
Compare BRSP & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRSP | AVIR |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.9M | 429.1M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BRSP | AVIR |
|---|---|---|
| Price | $4.13 | $5.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $6.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.5M | 239.9K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.03% | N/A |
| EPS Growth | ★ 75.24 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | $330,587,000.00 | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.98 | $2.78 |
| 52 Week High | $6.17 | $6.45 |
Technical Indicators
Market Signals| Indicator | BRSP | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 30.14 | 47.16 |
| Support Level | N/A | $5.09 |
| Resistance Level | $6.04 | $5.79 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 21.50 | 23.53 |
Price Performance
Historical ComparisonAbout BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.